AIMS: b-AP15 is a recently described inhibitor of the USP14/UCHL5 deubiquitinases (DUBs) of the 19S proteasome. Exposure to b-AP15 results in blocking of proteasome function and accumulation of polyubiquitinated protein substrates in cells. This novel mechanism of proteasome inhibition may potentially be exploited for cancer therapy, in particular for treatment of malignancies resistant to currently used proteasome inhibitors. The aim of the present study was to characterize the cellular response to b-AP15-mediated proteasome DUB inhibition. RESULTS: We report that b-AP15 elicits a similar, but yet distinct, cellular response as the clinically used proteasome inhibitor bortezomib. b-AP15 induces a rapid apoptotic response, associated with enhanced induction of oxidative stress and rapid activation of Jun-N-terminal kinase 1/2 (JNK)/activating protein-1 signaling. Scavenging of reactive oxygen species and pharmacological inhibition of JNK reduced b-AP15-induced apoptosis. We further report that endoplasmic reticulum (ER) stress is induced by b-AP15 and is involved in apoptosis induction. In contrast to bortezomib, ER stress is associated with induction of α-subunit of eukaryotic initiation factor 2 phosphorylation. INNOVATION: The findings establish that different modes of proteasome inhibition result in distinct cellular responses, a finding of potential therapeutic importance. CONCLUSION: Our data show that enhanced oxidative stress and ER stress are major determinants of the strong apoptotic response elicited by the 19S DUB inhibitor b-AP15.
AIMS: b-AP15 is a recently described inhibitor of the USP14/UCHL5 deubiquitinases (DUBs) of the 19S proteasome. Exposure to b-AP15 results in blocking of proteasome function and accumulation of polyubiquitinated protein substrates in cells. This novel mechanism of proteasome inhibition may potentially be exploited for cancer therapy, in particular for treatment of malignancies resistant to currently used proteasome inhibitors. The aim of the present study was to characterize the cellular response to b-AP15-mediated proteasome DUB inhibition. RESULTS: We report that b-AP15 elicits a similar, but yet distinct, cellular response as the clinically used proteasome inhibitor bortezomib. b-AP15 induces a rapid apoptotic response, associated with enhanced induction of oxidative stress and rapid activation of Jun-N-terminal kinase 1/2 (JNK)/activating protein-1 signaling. Scavenging of reactive oxygen species and pharmacological inhibition of JNK reduced b-AP15-induced apoptosis. We further report that endoplasmic reticulum (ER) stress is induced by b-AP15 and is involved in apoptosis induction. In contrast to bortezomib, ER stress is associated with induction of α-subunit of eukaryotic initiation factor 2 phosphorylation. INNOVATION: The findings establish that different modes of proteasome inhibition result in distinct cellular responses, a finding of potential therapeutic importance. CONCLUSION: Our data show that enhanced oxidative stress and ER stress are major determinants of the strong apoptotic response elicited by the 19S DUB inhibitor b-AP15.
Authors: Yang Yu; Yanling Zhao; Yihui Fan; Zhenghu Chen; Hui Li; Jiaxiong Lu; Kevin Guo; Sarah E Woodfield; Sanjeev A Vasudevan; Jianhua Yang; Jed G Nuchtern Journal: Mol Cancer Ther Date: 2019-04-08 Impact factor: 6.261
Authors: Pershang Farshi; Rahul R Deshmukh; Joseph O Nwankwo; Richard T Arkwright; Boris Cvek; Jinbao Liu; Q Ping Dou Journal: Expert Opin Ther Pat Date: 2015-06-16 Impact factor: 6.674
Authors: Karla D Passalacqua; Marie-Eve Charbonneau; Nicholas J Donato; Hollis D Showalter; Duxin Sun; Bo Wen; Miao He; Hanshi Sun; Mary X D O'Riordan; Christiane E Wobus Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191